Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23898480 | 1.00 | TSHR (0.36) | TSHRS1PR3MAOBMAOAPLA2G2A | |
| SCHEMBL23898547 | 1.00 | TSHR (0.36) | TSHRS1PR3MAOBMAOAPLA2G2A | |
| SCHEMBL23898408 | 0.93 | TSHR (0.36) | TSHRS1PR3MAOAPLA2G2AFFAR4 | |
| SCHEMBL23898411 | 0.93 | TSHR (0.36) | TSHRS1PR3MAOAPLA2G2AFFAR4 | |
| SCHEMBL23886775 | 0.92 | GAA (0.34) | TSHRS1PR3MAOBPLA2G2AFFAR4 | |
| SCHEMBL23898386 | 0.92 | MALT1 (0.34) | S1PR3PLA2G2AFFAR4CNR2CNR1 | |
| SCHEMBL23886774 | 0.92 | GAA (0.34) | TSHRS1PR3MAOBPLA2G2AFFAR4 | |
| SCHEMBL23898396 | 0.92 | MALT1 (0.34) | S1PR3PLA2G2AFFAR4CNR2CNR1 | |
| SCHEMBL23886802 | 0.92 | GAA (0.34) | TSHRS1PR3MAOBPLA2G2AFFAR4 | |
| SCHEMBL30176311 | 0.92 | GAA (0.34) | TSHRS1PR3MAOBPLA2G2AFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-26 | — | — | US | disclosed |
| WO-2021203007-A1 | SUBSTITUTED 5-HYDROXYINDOLE COMPOUNDS AS MODULATORS OF ALPHA-1 ANTITRYPSIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339915-A1 | MODULATORS OF ALPHA-1 ANTITRYPSIN | SERPINA2, SERPINA3, SERPINB1 | TSHR 1985/4885S1PR3 3903/4885MAOB 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.